Integrating Group Production Operations and Lowering Costs
First written in FY2017. 4 of 11 entries say "Advanced", first in FY2018-Q1. Latest entry: FY2021-Q3.
1 other company's latest entry also says "Cited as achieved".
- FY2021-Q3Cited as achievedAnnual report
「As another major change among the Company's affiliated companies, effective 1 April 2020, an absorption-type merger was carried out with キョーリン製薬グループ工場㈱ as the surviving company and キョーリンメディカルサプライ㈱ as the absorbed company.」
The absorption-type merger of キョーリンメディカルサプライ㈱ is restated as a completed change among affiliated companies related to the consolidation of the production structure. - FY2021-Q1AdvancedAnnual report
「As another major change among the Company's affiliated companies, effective 1 April 2020, an absorption-type merger was carried out with キョーリン製薬グループ工場㈱ as the surviving company and キョーリンメディカルサプライ㈱ as the absorbed company.」
In connection with the consolidation of the Group's production structure, キョーリンメディカルサプライ㈱ was absorbed into キョーリン製薬グループ工場㈱ effective 1 April 2020. - FY2019RestatedAnnual report
「The Company consolidated the Group's production functions at the new production subsidiary, キョーリン製薬グループ工場㈱, which began full-scale operations on 1 April 2018.」
The consolidation of production functions and the start of full-scale operations on 1 April 2018 were confirmed, and the Company continues to pursue overall optimization and cost reductions. - FY2019-Q3RestatedAnnual report
「As another major change among the Company's affiliated companies, in the prescription pharmaceutical business, an absorption-type merger was carried out effective 1 April 2018, with キョーリン製薬グループ工場㈱ (Chiyoda-ku, Tokyo) as the surviving company and キョーリン製薬グループ工場㈱ (Koka, Shiga) as the absorbed company.」
The absorption-type merger of the production subsidiary in Koka, Shiga, associated with the consolidation of the Group's production functions, continues to be reported as a change among affiliated companies effective 1 April 2018. - FY2019-Q2RestatedAnnual report
「The Company will consolidate its production functions at キョーリン製薬グループ工場㈱ and strongly promote overall optimization of intra-Group production and cost reductions.」
Following completion of the consolidation of production functions, the Company continues to promote overall optimization of intra-Group production and cost reductions. - FY2019-Q1RestatedAnnual report
「On 1 April 2018, the Company integrated the Noshiro Plant of its consolidated subsidiary 杏林製薬㈱, the Production Division of キョーリン リメディオ㈱ and キョーリン製薬グループ工場㈱ (Koka, Shiga) into the new production subsidiary, キョーリン製薬グループ工場㈱ (Chiyoda-ku, Tokyo), which began full-scale operations on the same day.」
The consolidation of production functions was completed on 1 April 2018, and the new production subsidiary began full-scale operations on the same day. - FY2018AchievedAnnual report
「On 1 April 2018, the Company consolidated the Group's production functions.」
The integration of the Noshiro Plant, the Production Division and the Shiga Plant into the new production subsidiary and the consolidation of the Group's production functions were completed on 1 April 2018. - FY2018-Q3AdvancedAnnual report
「As part of its production operations initiatives, following the establishment in October 2017 of キョーリン製薬グループ工場㈱ (Chiyoda-ku, Tokyo) as the new production subsidiary, the Company's Board of Directors resolved at a meeting held in December to integrate the Noshiro Plant of the Company's consolidated subsidiary 杏林製薬㈱, the Production Division of キョーリン リメディオ㈱ and キョーリン製薬グループ工場㈱ (Koka, Shiga) into the new production subsidiary on 1 April 2018 (scheduled), thereby consolidating the Group's production functions.」
Following the establishment of the new production subsidiary, the Board of Directors approved the integration of the Noshiro Plant, the Production Division and the Shiga Plant, scheduled for 1 April 2018, and the consolidation of production functions. - FY2018-Q2AdvancedAnnual report
「In line with this policy, the Company established the new production subsidiary in October 2017.」
The plan to consolidate production functions progressed to the establishment of the new production subsidiary in October 2017. - FY2018-Q1AdvancedAnnual report
「At a meeting of the Company's Board of Directors held on 11 May 2017, the Company resolved to establish a new production subsidiary and consolidate the Group's production functions for the purpose of integrating its intra-Group production structure. Around April 2018, the Noshiro Plant of the Company's consolidated subsidiary 杏林製薬㈱ and the Production Division of キョーリン リメディオ㈱ are scheduled to be transferred to the new production subsidiary through an absorption-type company split, while キョーリン製薬グループ工場㈱, another consolidated subsidiary, is scheduled to be integrated into the new production subsidiary through an absorption-type merger.」
The Board of Directors approved the policy of establishing a new production subsidiary and put into concrete form a plan to integrate the plant and Production Division around April 2018. - FY2017First statedAnnual report
「To strengthen our low-cost operations, we will establish a new production subsidiary to integrate the Group’s production system and consolidate its production functions. We will work to level factory utilization and use assets efficiently, thereby building a competitive Group production system capable of supplying high-quality products reliably and at low cost.」
The initiative involves consolidating production functions in a new production subsidiary, leveling factory utilization and improving asset efficiency to transform the cost structure.